B. Riley Has Bearish Estimate for Immunic FY2024 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at B. Riley reduced their FY2024 earnings estimates for Immunic in a research report issued on Tuesday, November 26th. B. Riley analyst W. Wood now expects that the company will post earnings of ($0.97) per share for the year, down from their prior estimate of ($0.93). B. Riley has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($0.80) EPS.

A number of other analysts have also recently commented on the company. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. HC Wainwright assumed coverage on shares of Immunic in a report on Monday, November 25th. They set a “buy” rating and a $10.00 price objective on the stock. Leerink Partners reiterated an “outperform” rating and issued a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.80.

Immunic Stock Up 3.3 %

Shares of Immunic stock opened at $1.24 on Thursday. The firm has a market cap of $111.70 million, a PE ratio of -1.01 and a beta of 1.88. Immunic has a twelve month low of $0.97 and a twelve month high of $2.11. The business has a 50-day moving average price of $1.34 and a 200 day moving average price of $1.34.

Institutional Trading of Immunic

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in Immunic during the first quarter worth about $25,000. Jane Street Group LLC raised its position in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares during the period. State Street Corp lifted its holdings in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Immunic

In related news, Director Richard Alan Rudick purchased 87,300 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the acquisition, the director now owns 87,300 shares in the company, valued at $100,395. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 3.00% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.